Nicolas M. Barthelemy has served as a director of Repligen since June 2014. Mr. Barthelemy brings over 30 years of industry experience to the director role. Mr. Barthelemy served as President and CEO of bioTheranostics, a molecular diagnostics company, from September 2014 until February 2017. Prior to bioTheranostics, he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo in February 2014.
Prior to Life Technologies, Mr. Barthelemy was with Biogen Inc. for eight years, most recently as Vice President, Manufacturing and General Manager for the company's manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. He has been a Senior Advisor at Warburg Pincus since 2020.
Mr. Barthelemy received a M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Superieure de Physique et Chimie Industrielles, Paris.
Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.